Natco Pharma [NATCOPHARM] vs Dr. Lal PathLabs [LALPATHLAB] Detailed Stock Comparison

Natco Pharma Ltd.

NSE
Loading...

Dr. Lal PathLabs Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Natco Pharma Ltd. wins in 14 metrics, Dr. Lal PathLabs Ltd. wins in 6 metrics, with 0 ties. Natco Pharma Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Natco Pharma Ltd. Dr. Lal PathLabs Ltd. Better
P/E Ratio (TTM) 12.32 46.16 Natco Pharma Ltd.
Price-to-Book Ratio 2.22 10.20 Natco Pharma Ltd.
Debt-to-Equity Ratio 3.01 6.44 Natco Pharma Ltd.
PEG Ratio 0.89 -7.05 Natco Pharma Ltd.
EV/EBITDA 9.10 32.00 Natco Pharma Ltd.
Profit Margin (TTM) 34.13% 19.84% Natco Pharma Ltd.
Operating Margin (TTM) 17.38% 20.79% Dr. Lal PathLabs Ltd.
EBITDA Margin (TTM) 17.38% 20.79% Dr. Lal PathLabs Ltd.
Return on Equity 24.77% 22.08% Natco Pharma Ltd.
Return on Assets (TTM) 21.85% 17.93% Natco Pharma Ltd.
Free Cash Flow (TTM) $11.85B $5.15B Natco Pharma Ltd.
Dividend Yield 0.73% 1.56% Dr. Lal PathLabs Ltd.
1-Year Return -5.35% 8.45% Dr. Lal PathLabs Ltd.
Price-to-Sales Ratio (TTM) 4.21 9.15 Natco Pharma Ltd.
Enterprise Value $162.40B $228.83B Dr. Lal PathLabs Ltd.
EV/Revenue Ratio 3.56 8.59 Natco Pharma Ltd.
Gross Profit Margin (TTM) 79.44% 65.97% Natco Pharma Ltd.
Revenue per Share (TTM) $255 $160 Natco Pharma Ltd.
Earnings per Share (Diluted) $86.97 $31.61 Natco Pharma Ltd.
Beta (Stock Volatility) 0.19 0.10 Dr. Lal PathLabs Ltd.

Natco Pharma Ltd. vs Dr. Lal PathLabs Ltd. Stock Performance Analysis

Loading Price Chart...

NATCOPHARM
LALPATHLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Natco Pharma Ltd.-1.89%-2.38%-29.31%-10.42%-6.36%-4.57%
Dr. Lal PathLabs Ltd.0.91%4.53%0.82%20.51%13.04%7.03%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Natco Pharma Ltd.-5.35%37.05%-21.16%69.86%1,522.04%4,430.15%
Dr. Lal PathLabs Ltd.8.45%58.06%0.84%257.00%257.46%257.46%

Performance & Financial Health Analysis: Natco Pharma Ltd. vs Dr. Lal PathLabs Ltd.

MetricNATCOPHARMLALPATHLAB
Market Information
Market Cap i₹191.91B₹238.92B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i701,464392,728
90 Day Avg. Volume i888,169321,187
Last Close₹847.60₹1,616.00
52 Week Range₹789.00 - ₹1,226.80₹1,272.60 - ₹1,770.00
% from 52W High-30.91%-8.70%
All-Time High₹1,639.00 (Sep 09, 2024)₹4,245.50 (Sep 13, 2021)
% from All-Time High-48.29%-61.94%
Growth Metrics
Quarterly Revenue Growth0.36%0.11%
Quarterly Earnings Growth0.14%-0.06%
Financial Health
Profit Margin (TTM) i0.34%0.20%
Operating Margin (TTM) i0.17%0.21%
Return on Equity (TTM) i0.25%0.22%
Debt to Equity (MRQ) i3.016.44
Cash & Liquidity
Book Value per Share (MRQ)₹482.88₹143.09
Cash per Share (MRQ)₹178.93₹77.96
Operating Cash Flow (TTM) i₹19.26B₹4.66B
Levered Free Cash Flow (TTM) i₹18.85B₹4.87B
Dividends
Last 12-Month Dividend Yield i0.73%1.56%
Last 12-Month Dividend i₹6.50₹22.50

Valuation & Enterprise Metrics Analysis: Natco Pharma Ltd. vs Dr. Lal PathLabs Ltd.

MetricNATCOPHARM (Apr 24, 2026)LALPATHLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i12.3246.16
Forward P/E i27.2641.23
PEG Ratio i0.89-7.05
Price to Sales (TTM) i4.219.15
Price to Book (MRQ) i2.2210.20
Market Capitalization
Market Capitalization i₹191.91B₹238.92B
Enterprise Value i₹162.40B₹228.83B
Enterprise Value Metrics
Enterprise to Revenue i3.568.59
Enterprise to EBITDA i9.1032.00
Risk & Other Metrics
Beta i0.190.10
Book Value per Share (MRQ) i₹482.88₹143.09

Financial Statements Comparison: Natco Pharma Ltd. vs Dr. Lal PathLabs Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNATCOPHARM (2025)LALPATHLAB (2025)
Revenue/Sales i44.12B24.61B
Cost of Goods Sold i8.65B8.23B
COGS % of Revenue i19.6%33.4%
Gross Profit i35.46B16.38B
Gross Margin i80.4%66.6%
Research & Development i1.13BN/A
Operating Income (EBIT) i19.81B5.60B
Operating Margin i44.9%22.8%
EBITDA i24.58B7.74B
EBITDA Margin i55.7%31.5%
Pre-Tax Income i22.91B6.25B
Pre-Tax Income % of Revenue i51.9%25.4%
Income Tax i4.08B1.33B
Income Tax % of Revenue i9.2%5.4%
Net Income (Profit) i18.83B4.92B
Profit Margin i42.7%20.0%

Balance Sheet & Liquidity Metrics

MetricNATCOPHARM (2025)LALPATHLAB (2025)
Cash & Equivalents i1.20B2.93B
Total Current Assets i52.70B13.64B
Total Current Assets % of Revenue i119.5%55.4%
Total Current Liabilities i9.44B4.02B
Total Current Liabilities % of Revenue i21.4%16.3%
Long-Term Debt i46.00M1.03B
Long-Term Debt % of Revenue i0.1%4.2%
Total Shareholders Equity i76.12B22.06B
Retained Earnings i62.47B18.60B
Retained Earnings % of Revenue i141.6%75.6%
Property, Plant & Equipment i474.00M3.36B

Cash Flow Statement Comparison

MetricNATCOPHARM (2025)LALPATHLAB (2025)
Operating Cash Flow i19.26B4.66B
Operating Cash Flow % of Revenue i43.7%18.9%
Capital Expenditures i-3.06B-436.20M
Free Cash Flow i11.85B5.15B
FCF Margin i26.9%20.9%
Debt Repayment iN/A-833.34M
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricNATCOPHARMLALPATHLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i179.11M166.97M
Float Shares i83.44M75.55M
% Held by Insiders i50.55%54.91%
% Held by Institutions i11.35%31.54%
% Held by Public i38.10%13.55%

Dividend Analysis & Yield Comparison: Natco Pharma Ltd. vs Dr. Lal PathLabs Ltd.

MetricNATCOPHARMLALPATHLAB
Last 12-Month Dividend i₹6.50₹22.50
Last 12-Month Dividend Yield i0.73%1.56%
3-Year Avg Annual Dividend i₹7.25₹23.50
3-Year Avg Dividend Yield i0.24%0.51%
3-Year Total Dividends i₹21.75₹70.50
Ex-Dividend DateFeb 18, 2026Feb 05, 2026